ERBB2 and gastroesophageal junction adenocarcinoma: HER-2/neu-targeting mAb trastuzumab is approved for the treatment of HER-2/neu-overexpressing breast cancer and metastatic gastric or gastroesophageal junction adenocarcinoma [174].